Goldman Sachs Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 61.2%

Neg 61.2% Neu 0% Pos 0%

Goldman Sachs analyst David Roman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $28 to $25.